StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.69−0.12 (-4.27%)

Close on Nov 20, 2026Market cap $271.29MP/E –Yield –

Galectin Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2015 it was -$16.98M. The highest annual figure on record is -$5.68M in fiscal 2011.

Annual free cash flow

PeriodPeriod endValueChange
FY2015Dec 31, 2015-$16.98M–
FY2014Dec 31, 2014-$12.43M–
FY2013Dec 31, 2013-$7.48M–
FY2012Dec 31, 2012-$7.51M–
FY2011Dec 31, 2011-$5.68M–

More Galectin Therapeutics figures

See a number that looks wrong?